Evidence map›Paper›PMID 41509151›Full record

ArticleClinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology2026

Burosumab treatment for FGF23-related hypophosphatemia in a two-year-old girl with McCune-Albright syndrome.

Tomoki Saito, Kana Hiromoto, Naoya Morisada, Ryosuke Sakata, Tomohiro Ishii, Tomonobu Hasegawa, Keiichi Ozono, Kayo Ozaki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tomoki SaitoDepartment of Endocrinology and Metabolism, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
Kana HiromotoDepartment of Genome Medical Center, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
Naoya MorisadaDepartment of Genome Medical Center, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
Ryosuke SakataDepartment of Orthopedic Surgery, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
Tomohiro IshiiDepartment of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Tomonobu HasegawaDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Keiichi OzonoCenter for Promoting Treatment of Intractable Diseases, ISEIKAI International General Hospital, Osaka, Japan.
Kayo OzakiDepartment of Endocrinology and Metabolism, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

McCune-Albright syndrome (MAS) is a rare mosaic disorder caused by a gain-of-function pathogenic

Indexed as

burosumabFGF23fibrous dysplasiaGNAShypophosphatemiaMcCune-Albright syndrome

Identifiers

PMID41509151
PMCPMC12779380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.